Johnson & Johnson’s JNJ stock has been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since the end of June. It achieved the golden cross in mid-July. The 50-day ...
Johnson & Johnson JNJ will begin the earnings season for the drug & biotech sector when it reports its fourth-quarter and full-year 2025 results on Jan. 21. The Zacks Consensus Estimate for ...
J&J has gone through several shifts in recent years -- and demonstrated its strength. The company has many products and platforms that deliver billion-dollar revenue. Meanwhile, J&J's top-selling drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results